Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

Cell & Gene Therapy International Europe
3-5 November 2026
Hotel Palace BerlinBerlin, Germany
Book Now
Menu
Book
Key Sessions
Paolo Morgese
Regulatory Panel Discussion – Navigating the Evolving European Regulatory Landscape for Cell and Gene Therapies
Alliance for Regenerative Medicine
Lia Ferreras
Case Studies on Managing Complex CGT Potency Assays Through to Commercial
Orchard Therapeutics
keyboard_arrow_right

Thursday 5th November – Day 2 Main Conference - GMT (Greenwich Mean Time, GMTZ)

keyboard_arrow_leftSearch & Filter
search
Thursday 5th November – Day 2 Main Conference - GMT (Greenwich Mean Time, GMTZ)
search
Showing 1 of 1 Streams
08:30 - 09:00
Registration & Morning Coffee
Showing 4 of 4 Streams
09:00 - 09:10
Chairperson’s Opening Remarks: Cell Therapy Manufacturing & Analytics
09:10 - 09:40
Bridging Viral and Lipid Nanoparticle Worlds: Surface Engineering Lentiviral Vector-Based Nanoparticles for Targeted In Situ CAR-T Cell Therapy
  • Céline Jaudouin - Senior Formulation Scientist, Alaya.bio
09:40 - 10:10
Panel Discussion: Scale-Up Strategies: Navigating the Road Ahead for In Vivo CAR-T
  • Lorenz Mayr - Managing Director, BioMedTech Consulting GmbH
  • Matthias Bozza - Director, Head of Strategy and R&D, CPTx
  • Ulf Grawunder - Co-founder & CEO, T-CURX
10:10 - 10:40
Scientific Sponsored Track Presentation
09:00 - 09:10
Chairperson’s Opening Remarks: Gene Therapy Manufacturing & Analytics
09:10 - 09:40
Manufacturing Challenges and Control Strategies For Dual AAV Vectors - Characterisation and Analytical Methods
  • Christine Le Bec - Deputy CTO, Head of Analytical Development & QC, Sensorion
09:40 - 10:10
Case Study: Potency Strategy and Regulatory Interactions for Hemgenix
  • Simone Zanetti - Global Head of QC Analytical Technologies, Gene Therapy, CSL Behring
10:10 - 10:40
Case Studies on Managing Complex CGT Potency Assays Through to Commercial
  • Lia Ferreras - Senior Scientist – Analytical Development Group, Orchard Therapeutics
09:05 - 09:10
Chairperson's Opening Remarks: Exosomes Europe 2026
09:10 - 09:40
Downstream Exosome Bottlenecks: Chromatography versus Ultracentrifugation
09:40 - 10:10
Smart EV Biomanufacturing: Balancing Yield, Purity & Scale from Lab to Clinic
  • Jan Schrooten - CEO, Antleron
10:10 - 10:40
Scientific Track Presentation: Downstream Purity & Quality Control
09:00 - 09:10
Welcome to LNPs Europe – Chairperson’s Welcome
09:10 - 09:40
Bridging Viral and Lipid Nanoparticle Worlds: Surface Engineering Lentiviral Vector-Based Nanoparticles for Targeted In Situ CAR-T Cell Therapy
  • Céline Jaudouin - Senior Formulation Scientist, Alaya.bio
09:40 - 10:10
Panel Discussion: Scale-Up Strategies: Navigating the Road Ahead for In Vivo CAR-T
  • Lorenz Mayr - Managing Director, BioMedTech Consulting GmbH
  • Matthias Bozza - Director, Head of Strategy and R&D, CPTx
  • Ulf Grawunder - Co-founder & CEO, T-CURX
10:10 - 10:40
Scientific Sponsored Track Presentation
Showing 2 of 2 Streams
10:40 - 11:20
Morning Coffee and Networking Break in Exhibition Hall
10:40 - 11:20
Poster Viewing - Meet the Poster Presenters

Explore groundbreaking research, meet the poster presenters and ask your questions.

Showing 4 of 4 Streams
11:20 - 11:50
Novel Analytical Technologies for Cell Therapy Product and Process Characterisation Strategies
  • Nicole Lund - Senior Director of Analytical & Quality Control, BlueRock Therapeutics
11:50 - 12:20
Use Cases of PAT Integration in CGT Processes and Implementation of Advanced Control Strategies
  • Rolando Matos - Senior Scientist, Cell and Gene Therapy Catapult
12:20 - 12:50
Panel Discussion: AI Integration in GMP Manufacturing
11:20 - 11:50
Mastering hcDNA: A Harmonized Approach for AAV Gene Therapies
  • Nic Preyat - Associate Director, Process Sciences, CMC Development - Gene Therapy, UCB
11:50 - 12:20
Use Cases of PAT Integration in CGT Processes and Implementation of Advanced Control Strategies
  • Rolando Matos - Senior Scientist, Cell and Gene Therapy Catapult
12:20 - 12:50
Panel Discussion: AI Integration in GMP Manufacturing
11:20 - 11:50
[Clinical Case Study] EVerGel: Our Current Journey Toward the Clinic
  • Clément Bonamy - Head of R&D Platform, Everzom
11:50 - 12:20
Manufacturing, regulatory compliance, and clinical development of EXO-101
  • A Representative from Exogenus Therapeutics - -, Exogenus Therapeutics
12:20 - 12:50
Scientific Track Presentation: Accelerating Exosomes into the Clinic
11:20 - 11:50
Enabling LNP-DNA Delivery to Target Peripheral Nerve Diseases
  • Gonzalo Fernández-Miranda - CEO and Co-Founder, CureAge Therapeutics
11:50 - 12:20
Targeted Lipid Nanoparticles Deliver Immune-Silent ssDNA to Generate CAR T Cells
  • Matthias Bozza - Director, Head of Strategy and R&D, CPTx
12:20 - 12:50
Sponsored Scientific Track Presentation: Designing Novel Chemistries and Novel Lipids to Overcome Bottlenecks - Endosomal Escape, Decrease Toxicity and Dosage Requirements
Showing 1 of 1 Streams
12:50 - 14:00
Networking Lunch in the Exhibition Hall
Showing 4 of 4 Streams
14:00 - 14:30
Off-The-Shelf Immune-Shielded iPSC-Derived Armored CAR γδ T Cells as a Novel Cell Therapy to Treat Hepatocellular Carcinoma
  • Stephanie Sontag - Senior Research Scientist, Evotec International GmbH
14:30 - 14:45
Cell Therapy Innovation Showcase: STAb Therapeutics
  • Carolina Pola - Chief Executive Officer, STAb Therapeutics
14:45 - 15:00
Cell Therapy Innovation Showcase: Captain T Cell
  • Alberto Sada Japp - Senior Director - R&D, Captain T Cell
15:00 - 15:15
ImmunoKey Ltd -Engineering Tumour Selectivity into Multi-Antigen CAR T-Cell Therapy. CARKey; A Dual-Receptor Platform for Solid Tumours
  • Gray Kueberuwa - Chief Executive Officer, ImmunoKey Ltd
15:15 - 15:30
NeutroGen Therapeutics- Restoring Innate Immunity: Developing Off-the-Shelf Neutrophil Transfusions for Severe Neutropenia
  • Lorenz Knackstedt - Chief Technology Officer, NeutroGen Therapeutics
14:00 - 14:30
Panel Discussion: Starting with the End in Mind: Designing Smart and Phase Appropriate Manufacturing for Successful Cell and Gene Therapy Development
14:30 - 14:45
Ikarovec - Development Of A Dual-Pathway Gene Therapy for Blindness
  • Andy Osborne - Vice President of Pre-Clinical Research, Ikarovec
14:45 - 15:00
Kindling Bio - Igniting Cancer Gene Therapy: Delivering Impact For Children and Beyond
  • Aleck Jones - CEO, Kindling Bio
15:00 - 15:15
Gene Therapy Innovation Showcase: EpiBlok Therapeutics GmbH
  • Regine Heilbronn - Co-Founder and CEO, EpiBlok Therapeutics
15:15 - 15:30
Cell Therapy Innovation Showcase: Blue Cell Therapeutics ApS
  • Søren Sheikh - CEO, Blue Cell Therapeutics ApS
14:00 - 14:30
Development of DB503, an engineered TSG-6 exosome therapeutic for Traumatic Brain Injury
  • Kuldeep Neote - CEO, Diadem Biotherapeutics
14:30 - 15:00
Genetically Programmed Extracellular Vesicles for Cell Targeting and Novel Therapeutic Development
  • Christopher Locher - CEO & Co-Founder, Versatope, USA
15:00 - 15:30
MEVs: A Programmable Oral Platform for Engineered Immunomodulatory Payloads Acting on Innate or Adaptive Immunity
  • Manuel Vega - CEO, AGS Therapeutics
14:00 - 14:30
R&D Innovations: Case Studies Next-Generation Therapeutic Applications of LNPs
  • Katia Lemdani - Director Research and Development, Neovacs
14:30 - 15:00
Engineering LNPs for Next Generation Vaccines & Therapeutics
  • Heinrich Haas - Chief Technology Officer, NeoVac
15:00 - 15:30
R&D Innovations: Case Studies Next-Generation Therapeutic Applications of LNPs
Showing 1 of 1 Streams
15:30 - 16:00
Afternoon Coffee and Networking Break in Exhibition Hall
Showing 3 of 3 Streams
16:00 - 17:00
Regulatory Panel Discussion – Navigating the Evolving European Regulatory Landscape for Cell and Gene Therapies
  • Paolo Morgese - VP Public Affairs EMEA, Alliance for Regenerative Medicine
16:00 - 17:00
PANEL DISCUSSION: Future Outlook: Industrialization of the EV Pipeline
  • Predicting the "mRNA moment" for exosome-based vaccine and therapy delivery
  • The evolution of cell-free therapeutics as a solution to scalability hurdles
  • Long-term vision for standardized, high-volume exosome manufacturing hubs
  • Final assessment of manufacturing breakthroughs needed in the next 5-8 years.
16:00 - 16:30
Refining LNP Design: Formulation Variables Influencing Biological Performance
  • Aadarash Zia - Senior Scientist - Drug Delivery, Medicines Discovery Catapult
16:30 - 17:00
Application of AI and Machine Learning in LNP Development
17:00 - 17:05
Close of Event 2026 – See You Next Year!
Wednesday 4th November – Day 1 Main Conference
Filter
Streams
Choose Day